We previously showed that severe hypoxia enhances the maintenance, in vitro, of normal stem cells capable of shortterm hematopoietic reconstitution (Cipolleschi et al.,
1,2 Ivanović et al., 3 and references therein), and that resistance to hypoxia defines hierarchical levels within hematopoietic populations. The study summarized here addressed the questions (a) whether cell subsets endowed with different levels of sensitivity to severe hypoxia were identifiable within clonal chronic myeloid leukemia (CML) cell populations and (b) whether such subsets differed as for BCR/Abl expression and sensitivity to imatinibmesylate.We found (Figure 1a ) that the number of viable K562 cells was markedly reduced in day-7 cultures (LC1) incubated in hypoxia not only with respect to normoxia (360-fold), but also time-zero (12-fold). Cells capable of generating colony in vitro (CFC) exhibited an even higher sensitivity to hypoxia (3-log reduction compared to time-zero). The culture-repopulating ability assay, developed to reveal hematopoietic stem cells of the short-term repopulating type, was then applied to CML cells. This assay estimates the culture-repopulating power of hematopoietic cells that have undergone selection (hypoxia) in a primary liquid culture (LC1) by means of their transfer to a nonselective (normoxia) secondary liquid culture (LC2) and a further incubation therein. 2, 3 After transferring cells selected in hypoxic LC1 to normoxic LC2, the number of viable cells was increased sixfold at day 14, whereas the increase in colony-forming cells (CFC) number was more marked (3-log) and already detectable at day 7 (1-log). The maintenance in hypoxia of progenitors responsible for LC2 repopulation (culture-repopulating cells; CRC), calculated by the ratio of the peak number of viable cells in LC2 to that in non-selective LC1 incubated in normoxia, was 94% for K562 cells, and comparable values were obtained for KCL22 and LAMA84 cells (Figure 1b) . Thus, CML cell lines included fully hypoxia-resistant CRC together with the highly hypoxia-sensitive CFC and bulk of population.
The progenitor subsets identified as above within K562 cells were then assayed for sensitivity to imatinib. Imatinib markedly reduced the viable cell and CFC numbers in normoxic, nonselective LC1. On the contrary, the treatment with imatinib (days 0-7) of LC2, carried out with cells recovered from hypoxic LC1, was completely ineffective on the expansion occurring in LC2 from day 7 to 14. Thus, incubation in hypoxia selected imatinib-resistant CRC (Figure 2a) . The effects of hypoxia or imatinib on BCR/abl and its product were then assessed. BCR/ Abl expression and phosphorylation were suppressed in hypoxic LC1 (Figure 2b ), but BCR/abl transcription was not significantly affected (Figure 2c ), pointing to a post-transcriptional action of hypoxia. KCL22 and LAMA84 cells behaved similarly (data not shown). Thus, hypoxia-selected CML cells resulted at the same time imatinib-insensitive and independent of BCR/Abl signaling for their survival in culture. As these features are considered typical of CML progenitors responsible for minimal residual disease, 4 it is reasonable to infer that hypoxia-resistant CRC correspond to these progenitors.
Interestingly, LC2 repopulation appeared largely independent of BCR/Abl expression (Figure 2a and b) . BCR/Abl phosphorylation slightly increased starting from day 7, when the number of CFC, but not that of viable cells, was increased (1-log) as an effect of transfer to normoxia (Figure 1a and b) . Thus, the rescue of BCR/Abl expression in the course of clonal expansion most likely occurred at the CFC level, in keeping with the finding that BCR/Abl expression increases mainly in committed clonogenic progenitors during disease progression. 5 Clonal expansion in LC2 eventually led to the return to an imatinib-sensitive state, as observed following the transfer to LC3 (Figure 2a ). This was paralleled by rescue of full BCR/Abl expression (Figure 2b ). In this respect, it is worth pointing out that LC3 cells, when reexposed to hypoxia, were as much hypoxia-sensitive as LC1 cells (data not shown). Thus, hypoxia/imatinib-resistant CRC eventually repopulate cultures with BCR/Abl-dependent, hypoxia/ imatinib-sensitive cells. CRC, however, remains a minor, but constant, component of the population. Figure 2b also shows that full BCR/Abl expression was recovered at day 14 in imatinib-treated LC2 cells, while untreated LC2 cells required a further expansion in LC3. Thus, imatinib primed the hypoxiaresistant, BCR/Abl-independent cell subset to rescue BCR/Abl expression more rapidly once environmental conditions (normoxia) permissive for clonal expansion were restored. This is in keeping with the finding that the re-establishment of permissive conditions following imatinib removal determines BCR/Abl overexpression. 6 The complete removal of BCR/Abl in hypoxia suggests that its expression may be detrimental to the maintenance in hypoxia of BCR/Abl-independent CRC. A number of reasons may underlie this antagonism, and accumulation of excess BCR/Abl was found deleterious to cell viability and growth. 7 It was also shown that BCR/Abl-induced growth factor independence is mediated at least in part by IL3 signaling. 8 Our finding that IL3 impairs the maintenance in hypoxia of hypoxia-resistant normal hematopoietic stem cells 3 might thus explain the intolerance of leukemic CRC to BCR/Abl expression.
In conclusion, CML cell lines are, in spite of their clonality, funcionally heterogeneous, as they were found to comprise both hypoxia-sensitive CFC and hypoxia-resistant stem cells of the short-term repopulating type. The latter were completely imatinib-insensitive and lacked BCR/Abl protein, but not mRNA, expression. This is, to our knowledge, the first report that links the suppression of imatinib-sensitivity and BCR/Abl expression to hypoxia-resistance in CML cells, pointing to a metabolic peculiarity of immature leukemia progenitors which is relevant to the maintenance of cancer stem cells in solid tumors. Further studies are needed to clarify the mechanism of the hypoxiainduced downmodulation of BCR/Abl as well as the cell kinetics linking hypoxia-insensitive CRC to the hypoxia-sensitive CFC and cell bulk.
